SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CALABRO', Luana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.879
NA - Nord America 2.337
EU - Europa 875
SA - Sud America 585
AF - Africa 71
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.750
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.214
SG - Singapore 1.220
BR - Brasile 436
CN - Cina 418
VN - Vietnam 401
HK - Hong Kong 363
IT - Italia 226
DE - Germania 118
FR - Francia 99
JP - Giappone 99
ID - Indonesia 97
GB - Regno Unito 95
RU - Federazione Russa 92
IN - India 80
FI - Finlandia 77
MX - Messico 70
AR - Argentina 59
BD - Bangladesh 37
CA - Canada 36
NL - Olanda 32
ZA - Sudafrica 32
UA - Ucraina 28
IQ - Iraq 25
TR - Turchia 25
PL - Polonia 22
EC - Ecuador 21
AT - Austria 18
PH - Filippine 16
VE - Venezuela 16
CO - Colombia 14
ES - Italia 13
SA - Arabia Saudita 13
PY - Paraguay 10
SE - Svezia 10
AE - Emirati Arabi Uniti 9
CL - Cile 9
KR - Corea 9
PK - Pakistan 9
JO - Giordania 8
MA - Marocco 8
MY - Malesia 8
BO - Bolivia 7
LT - Lituania 7
UY - Uruguay 7
CH - Svizzera 6
UZ - Uzbekistan 6
DZ - Algeria 5
EG - Egitto 5
KE - Kenya 4
NP - Nepal 4
PA - Panama 4
PE - Perù 4
TN - Tunisia 4
AL - Albania 3
BE - Belgio 3
BG - Bulgaria 3
BY - Bielorussia 3
PS - Palestinian Territory 3
RS - Serbia 3
AM - Armenia 2
AU - Australia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BN - Brunei Darussalam 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
GA - Gabon 2
HN - Honduras 2
IL - Israele 2
KH - Cambogia 2
KW - Kuwait 2
KZ - Kazakistan 2
LV - Lettonia 2
MK - Macedonia 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
AO - Angola 1
BF - Burkina Faso 1
BJ - Benin 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GE - Georgia 1
GN - Guinea 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
IE - Irlanda 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
ML - Mali 1
Totale 6.736
Salva come PNG Salva come JPEG
Città #
Singapore 670
Ashburn 466
Santa Clara 416
San Jose 379
Hong Kong 361
Ho Chi Minh City 146
Hanoi 103
Tokyo 95
Beijing 94
Council Bluffs 86
Jakarta 74
Lauterbourg 73
Helsinki 61
Mexico City 49
Los Angeles 43
São Paulo 40
Chandler 39
Chicago 39
London 30
New York 30
Bologna 29
Dallas 29
Nuremberg 25
Milan 22
Orem 21
Munich 19
Da Nang 18
Ferrara di Monte Baldo 18
Salt Lake City 18
Warsaw 18
Falkenstein 17
Haiphong 17
Hefei 17
Shanghai 16
Hải Dương 14
Johannesburg 14
Montreal 14
Brasília 13
Denver 13
New Delhi 13
Baghdad 12
Rio de Janeiro 12
Biên Hòa 11
Brooklyn 11
Lappeenranta 11
Moscow 11
Phoenix 11
Chennai 10
Florence 10
Frankfurt am Main 10
San Francisco 10
Stockholm 10
Buffalo 9
Dhaka 9
Elk Grove Village 9
Ferrara 9
Quito 9
Vienna 9
Amman 8
Düsseldorf 8
Guangzhou 8
Guayaquil 8
Paris 8
Amsterdam 7
Belo Horizonte 7
Boston 7
Montevideo 7
Santiago 7
Seattle 7
Ankara 6
Assago 6
Asunción 6
Atlanta 6
Buenos Aires 6
Bến Tre 6
Curitiba 6
Fortaleza 6
Hounslow 6
Houston 6
Manchester 6
Poplar 6
Yongsan-gu 6
Can Tho 5
Guarulhos 5
Jeddah 5
Juiz de Fora 5
Manaus 5
Princeton 5
Recife 5
Shenzhen 5
Sterling 5
São Gonçalo 5
Tampa 5
Thái Bình 5
Toronto 5
Turku 5
Cape Town 4
Charlotte 4
Chiswick 4
Ha Long 4
Totale 4.088
Salva come PNG Salva come JPEG
Nome #
Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge 163
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 135
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 134
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 125
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 124
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy 116
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up 113
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial 108
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy 106
Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014 99
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study 97
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial 96
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival 96
Circulating haemopoietic and endothelial progenitor cells are decreased in COPD 92
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 92
Biomarkers for immune checkpoint inhibitors--authors' reply 90
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 89
Challenges in lung cancer therapy during the COVID-19 pandemic 89
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications 89
Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignancies 89
"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015 87
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC 86
The emerging role of cancer nanotechnology in the panorama of sarcoma 86
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 82
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 81
Cancer bio‑immunotherapy XVI annual NIBIT‑(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy 80
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 79
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 78
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study 78
Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center 77
COVID and Lung Cancer 77
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870.893 76
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 76
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases 75
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial 75
Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis 75
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 72
Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer 71
Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013 70
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study 70
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer 70
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study 70
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 69
Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications 66
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 65
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 65
Primary hepatic epithelioid hemangioendothelioma progressively responsive to Interferon-alpha: is there room for novel anti-angiogenetic treatments? 64
Profilo lipidico nelle neoplasie ematologiche [Lipid profile in haematological malignancies] 64
Markers of endothelial and platelet status in patients with essential thrombocytemia and polycythemia vera 64
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial 63
Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line 62
The future of mesothelioma treatment: time to shift gear 61
Differential levels of solubile Endoglin (CD105) in myeloid malignancies 61
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy 59
Methimazole-induced agranulocytosis and quick recovery with G-CSF: case report 58
Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukaemia and long survival synthesize decorin 58
Increased concentration of circulating acid glycosaminoglycans in chronic lymphocytic leukemia and essential thrombocytaemia 58
Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells 57
L'ipersplenismo: Attualità e prospettive [Hypersplenism: Current status and perspectives] 57
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 56
Differential levels of solubile angiopoietin-2 and Tie-2 in patients with haematological malignancies 56
Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implication 56
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease? 56
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 55
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy 55
Soluble angiogenic factors: implications for chronic myeloproliferative disorders 55
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 54
Ipilimumab experience in heavily pre-treated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 53
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients 53
Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population 52
Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 52
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT) 52
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012 51
Levels of solubile angiogenin in chronic myeloid malignancies: clinical implications 51
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 51
Expression and regulation of the B7-H3 receptor in human mesothelial and mesothelioma cells: a novel target for immunotherapeutic applications 50
P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients 49
Epigenetically regulated clonal heretability of CTA expression profiles in human melanoma 48
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 48
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 48
Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain 48
Epigenetic immunomodulation of hematopoietic malignancies 47
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 47
Targeting of HLA-DR molecules transduces agonistic functional signals in Cutaneous melanoma 47
ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies 45
Thymosin α1 in melanoma from the clinical trial setting to the daily practice and beyond 45
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 45
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 44
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma 43
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010 42
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 41
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 38
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 36
Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study 34
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients 32
Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT) 27
Immunotherapy of brain metastases: breaking a “dogma” 27
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 26
Immune checkpoint blockade in malignant mesothelioma 24
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial 23
Totale 6.746
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.851
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 292
Totale 54.143
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202234 0 0 0 0 0 0 0 0 0 0 0 34
2022/2023168 5 46 3 2 48 6 5 9 22 2 10 10
2023/2024260 10 47 21 13 19 4 4 15 9 13 20 85
2024/20251.877 81 125 172 29 237 234 67 53 198 398 173 110
2025/20264.523 370 206 484 614 672 184 563 309 499 622 0 0
Totale 6.862